Abstract
Purpose: The combination of the antiangiogenic antibody bevacizumab with standard chemotherapy has improved the prognosis in patients with metastastic colorectal cancer and other advanced cancers. The role of combined anti-VEGF and chemotherapy in metastastic melanoma is just starting to be elucidated. Methods: We tested this notion in three patients with advanced and therapy-refractory melanoma. Results: Interestingly, two patients achieved objective regressions after three courses of therapy; the third patient, albeit progressing demonstrated a pronounced liquid necrosis in bulky lymphnode metastasis. Conclusion: Further studies are warranted to scrutinise these impressive therapeutic effects on the combination of bevacizumab and chemotherapy in melanoma.
| Original language | English |
|---|---|
| Journal | Journal of Cancer Research and Clinical Oncology |
| Volume | 133 |
| Issue number | 11 |
| Pages (from-to) | 897-901 |
| Number of pages | 5 |
| ISSN | 0171-5216 |
| DOIs | |
| Publication status | Published - 11.2007 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver